Prophylactic therapy with subcutaneous C1 inhibitor reduces hereditary angioedema attacks

Long-term subcutaneous treatment with a C1 inhibitor decreased the frequency and severity of hereditary angioedema attacks as well as the use of on-demand medications, according to a study published in Allergy and Asthma Proceedings.
C1 inhibitors have an over 30-year track record of safety for treating patients with hereditary angioedema (HAE), including children and adults, and pregnant and lactating women, Timothy Craig, DO, clinical researcher with the department of medicine, pediatrics and biomedical sciences at Pennsylvania State University, told Healio.
“The concern is that prior

Long-term subcutaneous treatment with a C1 inhibitor decreased the frequency and severity of hereditary angioedema attacks as well as the use of on-demand medications, according to a study published in Allergy and Asthma Proceedings.
C1 inhibitors have an over 30-year track record of safety for treating patients with hereditary angioedema (HAE), including children and adults, and pregnant and lactating women, Timothy Craig, DO, clinical researcher with the department of medicine, pediatrics and biomedical sciences at Pennsylvania State University, told Healio.
“The concern is that prior